The Effect of Repeated Administration of Ipodate (Oragrafin) in Hyperthyroidism*

Publisher Website
Google Scholar
Abstract
This report describes the effect of administration of repeated doses of ipodate (Oragrafin; 3 g orally every third day for five doses) in six hyperthyroid patients. Baseline serum concentrations of immunoassayable T3, rT3, and T4 were 926 ± 206 ng/100 ml, 165 ± 31 ng/100 ml and 21 ± 2.7 μg/100 ml (mean ± SEM), respectively. Within 24 h after the first dose of ipodate, serum T3 fell by 54% and it remained between 66–77% below baseline until the third day after the fifth dose; subsequently, there was a gradual recovery from the effect of ipodate. Serum T4 also decreased after ipodate administration; it was 23–31% lower than baseline from the second day after the third dose to the sixth day after the fifth dose. Serum rT3 increased after each dose of ipodate; peak values of 97%–203% above baseline value were observed at 24–48 h after each dose. There was a subjective improvement in clinical symptoms of hyperthyroidism in all cases. Resting pulse rate and pulse pressure dropped significantly (P < 0.02) by the ninth day of study and remained so thereafter. Body weight increased significantly by the ninth day of the study. The various data suggest that ipodate may serve as a useful adjunct in the early treatment of hyperthyroidism.